Innovative tBE Base Editing Therapy Shows Remarkable Success in Treating Blood Disorders
On September 7, 2026, a significant breakthrough was reported in the realm of medical research, particularly in gene editing for blood disorders. Researchers from CorrectSequence Therapeutics (Correctseq) published a comprehensive study in "Cell Stem Cell" detailing their findings on tBE-mediated base editing therapy for sickle cell disease (SCD) and β-thalassemia. This groundbreaking therapy demonstrated robust efficacy and safety across various genetic backgrounds, marking a new era in the treatment of β-hemoglobinopathies.
The study highlights the achievements of the therapy, labeled CS-101/CS-206, which utilizes a transformer Base Editor (tBE) to perform precise genetic modifications. This sophisticated method allows for the editing of the HBG1/2 promoter region within patient-derived hematopoietic stem and progenitor cells (HSPCs), reactivating γ-globin expression and improving hemoglobin levels.
Previously, five Chinese patients with transfusion-dependent β-thalassemia were treated with CS-101, and all achieved independence from blood transfusions. Building on this success, the recent study expanded its focus to include four additional patients from diverse backgrounds, showcasing the treatment's versatility. These patients hailed from Nigeria, Laos, Malaysia, and Pakistan, and included individuals with both SCD and β-thalassemia.
Remarkably, each patient exhibited a rapid and sustainable response to the treatment. For instance, a 21-year-old female patient from Nigeria, who experienced frequent vaso-occlusive crises prior to treatment, achieved significant improvements in her condition. Within mere weeks of the infusion, she displayed neutrophil and platelet engraftment and notable increases in hemoglobin levels—rising from 7.7 g/dL to a remarkable 12.9 g/dL within three months. After 15.5 months of follow-up, the patient remained free from vaso-occlusive crises, an impressive milestone in her recovery journey.
The remaining TDT patients also displayed commendable results, achieving transfusion independence and sustained increases in hemoglobin levels. These promising outcomes are particularly critical given that β-hemoglobinopathies impact hundreds of thousands of newborns globally each year. The study’s findings affirm the broad applicability of tBE therapy as it addresses the various genetic mutations prevalent among different populations.
The clinical data from this research underscores the therapy's superiority compared to existing nuclease-based gene editing techniques. For example, tBE therapy achieved faster neutrophil engraftment (13 days) juxtaposed with the 27 days required for Cas9 methods, and showed higher levels of sustained fetal hemoglobin (HbF) concentrations, exceeding those seen with traditional gene editing approaches. Furthermore, because tBE does not induce DNA double-strand breaks (DSBs), it circumvents the activation of p53, thus reducing potential side effects such as apoptosis and chromosomal rearrangements.
Looking ahead, Correctseq's trajectory in gene editing appears promising. Since the initiation of their clinical development, their product CS-101 has treated over 30 patients across multiple continents, boasting an unwavering 100% success rate in achieving transfusion independence or freedom from vaso-occlusive crises. With CS-101 being the world’s first base-editing therapy in clinical development—initiated in October 2023 and already in pivotal trials—the potential of this innovative therapy could revolutionize patient outcomes in genetic disorders.
Dr. Mou Xiaodun, CEO of Correctseq, encapsulated the significance of these results, stating that the study validates the extensive applicability of tBE therapy across diverse genetic landscapes. The company’s commitment to further exploring RNA editing, prime editing, and mitochondrial DNA editing suggests that this is just the beginning of a transformative journey in treating a range of genetic disorders.
In summary, the advancements in tBE-mediated base editing therapy open new avenues for patients suffering from blood disorders, promising not only better health outcomes but also aiming to enhance the quality of life for those affected by sickle cell disease and β-thalassemia worldwide.
The study highlights the achievements of the therapy, labeled CS-101/CS-206, which utilizes a transformer Base Editor (tBE) to perform precise genetic modifications. This sophisticated method allows for the editing of the HBG1/2 promoter region within patient-derived hematopoietic stem and progenitor cells (HSPCs), reactivating γ-globin expression and improving hemoglobin levels.
Previously, five Chinese patients with transfusion-dependent β-thalassemia were treated with CS-101, and all achieved independence from blood transfusions. Building on this success, the recent study expanded its focus to include four additional patients from diverse backgrounds, showcasing the treatment's versatility. These patients hailed from Nigeria, Laos, Malaysia, and Pakistan, and included individuals with both SCD and β-thalassemia.
Remarkably, each patient exhibited a rapid and sustainable response to the treatment. For instance, a 21-year-old female patient from Nigeria, who experienced frequent vaso-occlusive crises prior to treatment, achieved significant improvements in her condition. Within mere weeks of the infusion, she displayed neutrophil and platelet engraftment and notable increases in hemoglobin levels—rising from 7.7 g/dL to a remarkable 12.9 g/dL within three months. After 15.5 months of follow-up, the patient remained free from vaso-occlusive crises, an impressive milestone in her recovery journey.
The remaining TDT patients also displayed commendable results, achieving transfusion independence and sustained increases in hemoglobin levels. These promising outcomes are particularly critical given that β-hemoglobinopathies impact hundreds of thousands of newborns globally each year. The study’s findings affirm the broad applicability of tBE therapy as it addresses the various genetic mutations prevalent among different populations.
The clinical data from this research underscores the therapy's superiority compared to existing nuclease-based gene editing techniques. For example, tBE therapy achieved faster neutrophil engraftment (13 days) juxtaposed with the 27 days required for Cas9 methods, and showed higher levels of sustained fetal hemoglobin (HbF) concentrations, exceeding those seen with traditional gene editing approaches. Furthermore, because tBE does not induce DNA double-strand breaks (DSBs), it circumvents the activation of p53, thus reducing potential side effects such as apoptosis and chromosomal rearrangements.
Looking ahead, Correctseq's trajectory in gene editing appears promising. Since the initiation of their clinical development, their product CS-101 has treated over 30 patients across multiple continents, boasting an unwavering 100% success rate in achieving transfusion independence or freedom from vaso-occlusive crises. With CS-101 being the world’s first base-editing therapy in clinical development—initiated in October 2023 and already in pivotal trials—the potential of this innovative therapy could revolutionize patient outcomes in genetic disorders.
Dr. Mou Xiaodun, CEO of Correctseq, encapsulated the significance of these results, stating that the study validates the extensive applicability of tBE therapy across diverse genetic landscapes. The company’s commitment to further exploring RNA editing, prime editing, and mitochondrial DNA editing suggests that this is just the beginning of a transformative journey in treating a range of genetic disorders.
In summary, the advancements in tBE-mediated base editing therapy open new avenues for patients suffering from blood disorders, promising not only better health outcomes but also aiming to enhance the quality of life for those affected by sickle cell disease and β-thalassemia worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.